<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:department>Dept of Medicine</gtr:department><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/50C7BE14-6221-494E-9076-7EDF455575C3"><gtr:id>50C7BE14-6221-494E-9076-7EDF455575C3</gtr:id><gtr:firstName>Yiannis</gtr:firstName><gtr:surname>Kallis</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0500428"><gtr:id>B340D42C-9B4D-4F2B-B5D8-312E47F1C76C</gtr:id><gtr:title>The Bone Marrow Origin of Hepatic Fibrosis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0500428</gtr:grantReference><gtr:abstractText>Liver damage (cirrhosis) is a consequence of chronic liver disease and is at present only curable by liver transplantation. Bone marrow cells are being investigated for use in the repair of many damaged organs, including the liver. Recent research into how cirrhosis develops, however, has shown that bone marrow derived cells can migrate to the damaged liver and can actually be implicated in the scarring process (fibrosis) itself. These cells, called the bone marrow-derived myofibroblasts, have been found in both humans and animal models of liver disease. This is a new and unexpected finding which requires further clarification.
A group under the supervision of Dr S. Forbes at Imperial College, London propose to conduct a series of experiments on these myofibroblast cells using laboratory mice which have a chronic liver disease similar to that seen in humans. The intention is to determine exactly where in the bone marrow the myofibroblast cell originates and to understand this cell?s contribution to scarring in the liver. Whether this scarring process can be altered will also be studied. This work should further the understanding of liver fibrosis and could aid the development of future treatments which halt and possibly reverse chronic liver disease.</gtr:abstractText><gtr:technicalSummary>Bone marrow stem cells may have the potential to enhance organ regeneration and are already being used in clinical trials (for example following myocardial infarction). We have already shown, however, that the bone marrow can contribute to scar-forming cells within the liver i.e. myofibroblasts. This recent finding is important as it has been identified in both animal models of liver disease and in patients with liver fibrosis of diverse aetiology. The main aim of our proposal is to further understand the external sources of liver fibrosis in chronic liver disease. We specifically plan to address the following objectives:

1. Define the bone marrow stem cell of origin contributing to the scar-forming cells within the liver.
2. Characterise the population of collagen-producing cells within the liver.
3. Quantify the relative contribution of intra- and extra-hepatic scar-forming cells to liver fibrosis. 
4. Characterise the capability of the bone marrow-derived myofibroblast to produce collagen.
5. Study whether the bone marrow can confer susceptibility or resistance to liver fibrosis.

We will undertake these investigations in an established mouse model of chronic liver disease which uses carbon tetrachloride to induce liver fibrosis. The tracking of cells originating from the bone marrow will be achieved by performing sex-mismatched bone marrow transplantation (female mice will receive male bone marrow transplants) prior to inducing liver damage. In-situ hybridisation for the Y chromosome will be used to localisebone marrow derived cells and will be combined with immunohistochemistry to identify bone marrow derived stellate cells and myofibroblasts. The Col1a2 transgenic mouse (supplied by Dr G. Bou-Gharios) and the Col1a1(r/r) transgenic mouse (supplied by Prof. J. Iredale) will be used in similar sequential experiments to localise bone marrow derived cells transcribing and depositing collagen respectively. Bone marrow transplantation from mice with enhanced and diminished fibrotic phenotypes (Col1a1(r/r) and Par-1 knockout respectively) will enable further investigation into the influence of the bone marrow on liver fibrosis. These proposed studies will hopefully shed more light on to the relationship between the bone marrow and the injured liver and may inform future therapeutic strategies to counter progressive liver fibrosis.</gtr:technicalSummary><gtr:fund><gtr:end>2008-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2005-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>217586</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>60CE2099-E6F5-44FE-AF91-88E26EB971C3</gtr:id><gtr:title>Bone marrow-derived cells contribute to cerulein-induced pancreatic fibrosis in the mouse.</gtr:title><gtr:parentPublicationTitle>International journal of experimental pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4482bb97dcf32b070249fa2f2a777a70"><gtr:id>4482bb97dcf32b070249fa2f2a777a70</gtr:id><gtr:otherNames>Lin WR</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0959-9673</gtr:issn><gtr:outcomeId>56ddee5f421ab7.16122426</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>45F8425C-7B8C-4341-845D-B1E0F2CF2698</gtr:id><gtr:title>Remodelling of extracellular matrix is a requirement for the hepatic progenitor cell response.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57cc8704e3792ad9d960f7c56d10fd49"><gtr:id>57cc8704e3792ad9d960f7c56d10fd49</gtr:id><gtr:otherNames>Kallis YN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>56ddee5eb49256.19337536</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DF5D10F2-7AF9-4681-9B4C-BCA6C6B69EFE</gtr:id><gtr:title>The bone marrow and liver fibrosis: friend or foe?</gtr:title><gtr:parentPublicationTitle>Gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57cc8704e3792ad9d960f7c56d10fd49"><gtr:id>57cc8704e3792ad9d960f7c56d10fd49</gtr:id><gtr:otherNames>Kallis YN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0016-5085</gtr:issn><gtr:outcomeId>56ddee5ee54621.70822759</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EC586F55-53F5-4758-9059-40ABB79BCDA7</gtr:id><gtr:title>Bone marrow cells in the liver: diverse cells, diverse effects.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1e856f187c428b37710fb66859cf2d23"><gtr:id>1e856f187c428b37710fb66859cf2d23</gtr:id><gtr:otherNames>Russo FP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>56ddee5f21ba88.97929457</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>A82E2DFA-544B-406D-88EB-D1EDE9F5F058</gtr:id><gtr:title>Proteinase activated receptor 1 mediated fibrosis in a mouse model of liver injury: a role for bone marrow derived macrophages.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57cc8704e3792ad9d960f7c56d10fd49"><gtr:id>57cc8704e3792ad9d960f7c56d10fd49</gtr:id><gtr:otherNames>Kallis YN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>56ddeeb163e543.43578938</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EBE17020-A5D9-4094-A810-6E1D86548BEC</gtr:id><gtr:title>Bone marrow stem cells and liver disease.</gtr:title><gtr:parentPublicationTitle>Gut</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/57cc8704e3792ad9d960f7c56d10fd49"><gtr:id>57cc8704e3792ad9d960f7c56d10fd49</gtr:id><gtr:otherNames>Kallis YN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2007-01-01</gtr:date><gtr:issn>0017-5749</gtr:issn><gtr:outcomeId>6BE33F6E81F</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0500428</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory><gtr:healthCategory><gtr:id>D81A471F-556F-4570-BF6A-5D197943223C</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>Oral and Gastrointestinal</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>CF950C9A-DB16-4E23-8AEB-94548777BCA1</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.1  Normal biological development and functioning</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>